Potential Impact of a Free Online HIV Treatment Response Prediction System for Reducing Virological Failures and Drug Costs after Antiretroviral Therapy Failure in a Resource-Limited Setting

Table 2

Annual costs of drugs and coformulations available to the Indian cohort.

	Annual cost (rupees)	Annual cost ($)*
Zidovudine	4,168.30	79.23
Lamivudine	2,357.90	44.82
Didanosine	3,615.20	68.72
Abacavir	12,634.84	240.16
Tenofovir	4,380.00	83.26
Nevirapine	3,197.40	60.78
Efavirenz	4,055.15	77.08
Lopinavir/ritonavir	30,127.10	572.66
Atazanavir	7,647.97	145.37
Ritonavir (atazanavir booster)	4,055.52	77.09
Nelfinavir	61,320.00	1,165.57
Coformulations
Zidovudine + lamivudine 300 : 150 mg	5,416.60	102.96
Tenofovir + lamivudine 300 : 300 mg	4,732.83	89.96
Tenofovir + emtricitabine 300 : 200 mg	7,300.00	138.76

 *1 Indian rupee = 0.019008 U.S. dollars.